PDS Biotech CFO Steps Down; CEO and Controller Assume Interim Financial Roles
PDSB is trading near its 52-week low of $0.195 (4.9% above the low) on elevated volume (3.0× avg).
Summary
PDS Biotech's CFO resigned effective September 12, 2026. The Controller and CEO will serve as interim Principal Accounting Officer and Principal Financial Officer, respectively.
Key Events · Executive and Board Changes · PDSB
-
CFO Resignation
Lars Boesgaard resigned as CFO, Principal Financial Officer, and Principal Accounting Officer effective September 12, 2026, to pursue other professional endeavors. The company stated the resignation is not due to any disagreement.
-
Interim Appointments
Controller Janetta Trochimiuk was appointed interim Principal Accounting Officer, and CEO Frank Bedu-Addo was appointed interim Principal Financial Officer, both effective September 12, 2026.
-
Compensation Details
Ms. Trochimiuk will continue to receive a base salary of $279,519.57 per year and remains eligible for equity awards, but received no equity awards in connection with the promotion.
-
Financial Distress Context
The leadership change occurs while the company has $5.6M in cash, a going concern warning, and Nasdaq delisting risk, as disclosed in the August 13, 2026 10-Q.
Analysis · PDSB · Life Sciences
CFO Lars Boesgaard resigned effective September 12, 2026, to pursue other opportunities. The company stated the resignation is not due to any disagreement. Controller Janetta Trochimiuk becomes interim Principal Accounting Officer, and CEO Frank Bedu-Addo takes on interim Principal Financial Officer duties. This leadership change comes at a critical time: the company has only $5.6M in cash, a going concern warning, and Nasdaq delisting risk. Losing the CFO amid such financial distress adds uncertainty, though the company moved quickly to fill the roles internally.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1668 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.2M. The 52-week trading range was $0.20 to $1.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.